KEYNOTE-B98: Phase Ib/II study of pembrolizumab plus investigational agents as second-line treatment for anti-PD-1/PD-L1-refractory extensive-stage small cell lung cancer (ES-SCLC) Meeting Abstract
| Authors: | Lai, W. C. V.; Ahn, M. J.; Shentzer, T.; Kowalski, D.; Cho, B. C.; Schmid, S.; Jové, M.; Huang, M.; Zhao, B.; El-Osta, H.; Navarro, A. |
| Abstract Title: | KEYNOTE-B98: Phase Ib/II study of pembrolizumab plus investigational agents as second-line treatment for anti-PD-1/PD-L1-refractory extensive-stage small cell lung cancer (ES-SCLC) |
| Meeting Title: | ESMO Immuno-Oncology Congress 2021 |
| Journal Title: | Annals of Oncology |
| Volume: | 32 |
| Issue: | Suppl. 7 |
| Meeting Dates: | 2021 Dec 8-11 |
| Meeting Location: | Virtual |
| ISSN: | 0923-7534 |
| Publisher: | Oxford University Press |
| Date Published: | 2021-12-01 |
| Start Page: | S1425 |
| End Page: | S1426 |
| Language: | English |
| ACCESSION: | WOS:000731051400116 |
| DOI: | 10.1016/j.annonc.2021.10.134 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: 116TiP -- Source: Wos |
